Type 2 diabetes: An overview

Clinical Chemistry

Volumn 45, Issue 8 II, 1999, Pages 1339-1345

  Lebovitz, Harold E ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN; METFORMIN; MIGLITOL; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETES MELLITUS; DRUG INDUCED DISEASE; GLUCOSE INTOLERANCE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOGLYCEMIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIVER FAILURE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

EID: 0032877903     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/45.8.1339     Document Type: Conference Paper

References (30)

1. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
2. Gerich JE. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev 1998;19:491-503.
3. Lebovitz HE. Diabetes mellitus in adults In: Rakel, RE, ed. Conn's current therapy 1998. Philadelphia: WB Saunders, 1998:545-53.
4. Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev 1998;19:477-90.
5. Hattersley AT. Maturity-onset diabetes of the young: clinical heterogeneity explained by genetic heterogeneity. Diabet Med 1998; 15:15-24.
6. Ravussin E, Valencia ME, Esparza J, Bennett PH, Schulz LO. Effects of a traditional lifestyle on obesity in Pima Indians. Diabetes Care 1994;17:1067-74.
7. Neel JV. Diabetes mellitus: a thrifty genotype rendered detrimental by progress? Am J Hum Genet 1962;14:353-62.
8. Barker DJP, Hales CN, Fall CHD, Osmond C, Phipps K, Clark PMS. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidemia (syndrome X): relation to reduced fetal growth. Diabetologia 1993;36:62-7.
9. Stern MP. The insulin resistance syndrome. In: Alberti KGMM, Zimmet P, DeFronzo RA, eds. International textbook of diabetes mellitus, Vol. 2. Chichester: John Wiley & Sons, 1997:255-83.
10. Lemiuez S, Prud'homme D, Nadeau A, Tremblay A, Bouchard C, Despres JP. Seven year changes in body fat and visceral adipose tissue in women, association with indices of plasma glucose-insulin homeostasis. Diabetes Care 1996;19:983-91.
11. Yki-Jarvinen H. Glucose toxicity. Endocr Rev 1992;13:415-31.
12. Walker M, Fulcher GR, Alberti KGMM. The assessment of insulin action in vivo. In: Alberti KGMM, Zimmet P, DeFronzo RA, eds. International textbook of diabetes mellitus, Vol. 2. Chichester: John B. Wiley & Sons, 1997:595-610.
13. Goudas VT, Dumesic DA. Polycystic ovary syndrome. Endocrinol Metab Clin N Am 1997;26:893-912.
14. Banerji MA, Lebowitz J, Chaiken RL, Gordon D, Kral JG, Lebovitz HE. Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects. Am J Physiol 1997;273:E425-32.
15. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L, et al. Activators of peroxisome proliferator-activated receptor gamma have depot specific effects on human preadipocyte differentiation. J Clin Investig 1997;100:3149-53.
16. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 1993;329:1988-92.
17. Lebovitz HE. The metabolic disease syndrome: lessons to be learned from racial and ethnic diversity. In: Schwartz CJ, Born GVR, eds. New horizons in diabetes mellitus and cardiovascular disease. London: Current Science, 1995:75-80.
18. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-53.
19. UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998;352:854-65.
20. UK Prospective Diabetes Study Group. Tight blood pressure control and the risk of macrovascular and microvascular complications in type 2 diabetes. Br Med J 1998;317:703-13.
21. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius E, et al. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) Randomized Trial. Lancet 1998;351:1755-62.
22. Sachs FM, Pfeffer MA, Move LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
23. Haffner SM, Lehto S, Ronnemar T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
24. Lebovitz HE. α-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev 1998;6:1-14.
25. Bell PM, Haddon DR, Metformin. Endocrinol Metab Clin N Am 1997;26:523-37.
26. Henry RR. Thaizolidinediones. Endocrinol Metab Clin N Am 1997; 26:553-73.
27. Lebovitz HE. Insulin secretogogues: sulfonylureas and repaglinide. In: Lebovitz HE, ed. Therapy for diabetes mellitus and related disorders, 3rd ed. Alexandria, VA: American Diabetes Association, 1998:160-70.
28. Burge MR, Schade DS. Insulins. Endocrinol Metab Clin N Am 1997;26:575-98.
29. Lebovitz HE. Effects of oral antihyperglycemic agents in modifying macrovascular risk factors in type 2 diabetes. Diabetes Care 1999;22(Suppl 3): C41-5.
30. Lebovitz HE. Combination therapy for hyperglycemia. In: Lebovitz HE, ed. Therapy for diabetes mellitus and related disorders, 3rd ed. Alexandria, VA: American Diabetes Association, 1998:211-9.